The University of Southampton
University of Southampton Institutional Repository

Advances in chemotherapy and targeted systemic therapies for Urothelial cancer

Advances in chemotherapy and targeted systemic therapies for Urothelial cancer
Advances in chemotherapy and targeted systemic therapies for Urothelial cancer
Systemic chemotherapy for cancer of the urothelial tract is used according to two main strategies. Neoadjuvant or adjuvant treatment combined with surgery and/or radiotherapy is aimed at cure of localised disease whilst treatment for advanced incurable disease allows for improved survival and palliation of symptoms. Cisplatin based combination regimens represent the standard of care in both of these settings and incorporation of gemcitabine has allowed for improvements in tolerability over older drugs. However, despite high objective response rates, impact on survival is modest. Targeted agents are now being incorporated into early phase clinical trials. These exciting new strategies hold promise for improved efficacy but with new challenges regarding toxicity profiles. This review will describe current evidence for the use of systemic chemotherapy for urothelial cancer and the state of the research evidence for use of the newer targeted agents.
urothelial cancer, bladder cancer, chemotherapy, systemic therapy
1574-8855
17-28
Crabb, Simon J.
bcd1b566-7677-4f81-8429-3ab0e85f8373
Wheater, Matthew J.
3691c3d8-8589-4693-a0dc-c6a8648cd7df
Crabb, Simon J.
bcd1b566-7677-4f81-8429-3ab0e85f8373
Wheater, Matthew J.
3691c3d8-8589-4693-a0dc-c6a8648cd7df

Crabb, Simon J. and Wheater, Matthew J. (2010) Advances in chemotherapy and targeted systemic therapies for Urothelial cancer. Current Drug Therapy, 5 (1), 17-28.

Record type: Article

Abstract

Systemic chemotherapy for cancer of the urothelial tract is used according to two main strategies. Neoadjuvant or adjuvant treatment combined with surgery and/or radiotherapy is aimed at cure of localised disease whilst treatment for advanced incurable disease allows for improved survival and palliation of symptoms. Cisplatin based combination regimens represent the standard of care in both of these settings and incorporation of gemcitabine has allowed for improvements in tolerability over older drugs. However, despite high objective response rates, impact on survival is modest. Targeted agents are now being incorporated into early phase clinical trials. These exciting new strategies hold promise for improved efficacy but with new challenges regarding toxicity profiles. This review will describe current evidence for the use of systemic chemotherapy for urothelial cancer and the state of the research evidence for use of the newer targeted agents.

This record has no associated files available for download.

More information

Published date: February 2010
Keywords: urothelial cancer, bladder cancer, chemotherapy, systemic therapy

Identifiers

Local EPrints ID: 172835
URI: http://eprints.soton.ac.uk/id/eprint/172835
ISSN: 1574-8855
PURE UUID: 4b999cec-cd1c-42f0-976a-3c2733147614
ORCID for Simon J. Crabb: ORCID iD orcid.org/0000-0003-3521-9064

Catalogue record

Date deposited: 31 Jan 2011 10:14
Last modified: 23 Jul 2022 01:51

Export record

Contributors

Author: Simon J. Crabb ORCID iD
Author: Matthew J. Wheater

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×